<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15747">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901886</url>
  </required_header>
  <id_info>
    <org_study_id>H-16022001</org_study_id>
    <nct_id>NCT02901886</nct_id>
  </id_info>
  <brief_title>REU-stop - Effect of Intensive Smoking Cessation Intervention on Smoking Cessation and Disease Activity in Patients With Rheumatoid Arthritis.</brief_title>
  <official_title>REU-stop - Effect of Intensive Smoking Cessation Intervention on Smoking Cessation and Disease Activity in Patients With Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Rheumatism Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Novo Nordic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Capital Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TrygFonden, Denmark</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test the effect of an intensive smoking cessation intervention
      (motivational counseling combined with nicotine replacement) on smoking cessation and
      disease activity in patients with Rheumatoid Arthritis (RA). Half of the patients will
      participate in a smoking cessation intervention; the other half will receive usual
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco smoking is a well-known environmental risk factor for developing rheumatoid
      arthritis (RA). The onset of RA can occur in all age groups, with the majority being women
      aged 50-60 years. RA is a chronic inflammatory disease and cannot be cured. However, the
      activity of the disease can be reduced by medication. During periods with high disease
      activity, patients experience increased pain and fatigue and subsequent restrictions in
      social life, psychical activity and activities of daily life. Furthermore, the inflammatory
      process underlying RA can cause pain, fatigue, reduced health-related quality of life and
      reduced physical function. Patients with RA are at increased risk of cardiovascular diseases
      similar to the risk demonstrated in patients with diabetes. Furthermore, several studies
      indicate that smokers with inflammatory arthritis tend to experience more pain and fatigue,
      and a reduced quality of life compared to non-smokers.

      The primary aim of this study is to examine if an intensive smoking cessation intervention
      leads to smoking cessation and reduced disease activity in patients with RA. Secondary aims
      are to examine the effect on the risk of cardiovascular diseases, lung function, psychical
      function, health-related quality of life, pain and fatigue in patients with RA.

      Material and Methods

      Study design: A multicenter randomized 2-armed controlled intervention study (RCT). It is
      not possible to blind patients or smoking cessation counsellors to the intervention. All
      outcomes will be assessed by blinded outcome assessors. Data on remaining secondary outcomes
      will be patient-reported. Baseline and outcome data will be collected at baseline before
      randomization, 3 months, 6 months, and 12 months post intervention.

      Study setting: Patients will be recruited from rheumatology outpatient clinics at University
      Hospital Rigshospitalet - Glostrup (Capital Region of Denmark), Frederiksberg Hospital
      (Capital Region of Denmark) and Preventive Cardio-Rheuma Clinic, Diakonhjemmet Hospital
      Oslo, Norway.

      Randomization and blinding: After accepting participation in the study, baseline data will
      be collected. Following this, patients will be randomized using computer-generated
      stratified block randomization (blocks of 6-10 patients). Patients will be allocated 1:1 to
      either 1) the intervention group (N = 75) or 2) the control group (N = 75).

      Data collection: Outcomes will be assessed four times up to 13.5 months post-intervention:
      1) at baseline 2) 3 months post-intervention 3) 6 months post-intervention 4) 12
      post-intervention.

      At baseline, patients will be asked to complete self-reported questionnaires regarding
      demographics, lifestyle, smoking history, consumption of pain medication and alcohol
      consumption. Charlson's co-morbidity Scale is used for assessing co-morbidity based on data
      from the patient's chart. In addition, data on medical treatment, IgM-RF (rheumatoid factor)
      and Anti-cyclic citrullinated peptide (Anti-CCP) status will be obtained from the DANBIO
      registry.

      At each subsequent follow-up, patients will be asked to complete self-reported
      questionnaires regarding smoking status, disease activity (FLARE instrument), psychical
      function (HAQ), and health-related quality of life (SF-36 and EQ-5D), pain (VAS scale) and
      fatigue (BRAF-NRS). All patient-reported questionnaires will be completed electronically
      using a tablet. The tablet is exclusively for use in this study. Arterial stiffness, blood
      pressure, pulse, weight and waist circumference will be assessed at baseline and all
      follow-up visits. Blood samples will be drawn and analyzed for C-reactive protein (CRP),
      triglycerides, cholesterol level and HbA1c.

      All outcomes excluding patient-reported outcomes will be assessed by project nurses blinded
      to the patients' group allocation.

      Ethics, confidentiality and dissemination: The study will be carried out in accordance with
      the Helsinki Declaration. The study has been approved by The Regional Committee on Health
      Research Ethics (H-16022001) and the Danish Data Protection Agency (I-suite number 04849).
      All data and information collected during the study will be handled in accordance with the
      Danish Data Protection Agency and Good Clinical Practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous smoking cessation at 3 months follow-up</measure>
    <time_frame>3 months post-intervention</time_frame>
    <description>Self-reported smoking status measured by 7 day point prevalence, biochemical validated by carbon monoxide (CO) in exhaled air assessed at 3 months follow-up (CO-Check, NEOMED GmbH; Germany).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of EULAR clinical response (delta DAS28 &gt; 0.6) at 3 months follow-up</measure>
    <time_frame>3 months post-intervention</time_frame>
    <description>The achievement of EULAR clinical response (delta DAS28 &gt; 0.6) is assessed using DAS28 (Disease Activity Score - based on 28 joint counts) 3 months post-intervention. The DAS28 score consists of four elements; C-reactive protein (CRP), number of swollen joint, number of painful joints (maximum 28) and a &quot;Global General Health&quot; VAS score. The joint count and &quot;Global General Health&quot; are assessed by a project nurse blinded to the patients' group allocation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported smoking status at 6 and 12 months post-intervention</measure>
    <time_frame>6 and 12 months post-intervention</time_frame>
    <description>Self-reported smoking status measured by 7 day point prevalence, biochemical validation by carbon monoxide (CO) in exhaled air assessed at 3 months follow-up (CO-Check, NEOMED GmbH; Germany).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR clinical response at 6 and 12 months post-intervention</measure>
    <time_frame>6 and 12 months post-intervention</time_frame>
    <description>Achievement of EULAR clinical response will be registered at 6 and 12 follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 at 3, 6 and 12 months post-intervention</measure>
    <time_frame>6 and 12 months post-intervention</time_frame>
    <description>Achievement of EULAR clinical response will be registered at 6 and 12 follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessed disease activity by the FLARE Instrument</measure>
    <time_frame>6 and 12 months post-intervention</time_frame>
    <description>The FLARE instrument (FI) is a patient self-assessment for detecting changes in disease activity among patients with RA. It is designed to detect both past and present disease activity. The questionnaire consists of 12 questions answered on a 10-point Likert scale (0 = completely agree, 10 = completely disagree). Higher scores indicate a flare.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of swollen and tender joints at 3, 6 and 12 months post-intervention</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Assessed by a person blinded to the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician and patient Global VAS</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Assessed by a person blinded to the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Measured using blood sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Arterial stiffness will be measured by pulse wave velocity (Mobil-O-Graph, IEM; Germany).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Serum lipids (cholesterol, triglycerides) are measured using blood sample (serum plasma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and pulse</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Blood pressure and pulse will be measured after 5 minutes of rest (lying position) (Mobil-O-Graph, IEM; Germany). If the blood pressure is higher than 140/90, we will do two additional measurements. The mean of the last two blood pressure measurements will be registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Body weight will be measured to the nearest 0.1 kg (without shoes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Waist circumference will be measured using a tape measure in centimeters (cm). For women &gt; 80 cm indicate an increased risk for cardiovascular disease, &gt; 88 cm indicates a significant increased risk for cardiovascular disease. For men &gt; 94 cm and &gt; 102 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Serum lipids are measured using blood sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Lung function will be assessed by FEV1. FEV1 will be measured by spirometer (EasyOneTM, Model 2001 diagnostic Spirometer, Model 2010 Cradle, NDD Medizintechnik AG; Switzerland).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Health Assessment Questionnaire (HAQ) is a standardized questionnaire to assess disability and psychical function in patients with RA. The instrument contains 25 items with four possible answers in 9 categories; dressing, rising from a seat, eating, walking, personal hygiene, stretching for an object, grabbing object, anxiety, sleep, depression and everyday activities. The questionnaire includes VAS scales for pain, fatigue and general health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Health-related quality of life (HR-QoL) is measured by the following two questionnaires:
SF-36 is a generic instrument measuring HR-QoL by 36 items on eight scales. The scales are; psychical function, psychical activity, limitations, pain, general health, vitality, social function, emotional activity limitations and mental health.
EuroQoL (EQ-5D) is a standardized instrument to provide a generic measure of HR-QoL. The questionnaire contains five items (movement, personal care, usual activities, pain and anxiety/depression) with five answer possibilities each.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Pain</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>Pain related to RA is assessed by the patient on a Visual Analog Scale (VAS). The patient puts a mark on a horizontal line that indicates his or her pain (from 0-10). The line starts with &quot;no pain&quot; and ends with &quot;worst imaginable pain&quot;. The scale is included in MDHAQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>3, 6 and 12 months post-intervention</time_frame>
    <description>The Bristol Rheumatoid Arthritis Fatigue Numeric Rating Scale (BRAF-NRS) is a numeric scale to assess fatigue in patients with RA. The scale includes three questions concerning the fatigue of the patient within the last seven days. The patient puts a mark on a horizontal line that indicates his or hers level of fatigue (from 0-10).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Intensive smoking cessation intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention includes 1) Individual motivational counseling according to the principles of motivational interviewing in combination with 2) nicotine replacement therapy.
Individual motivational counseling. The intervention consists of five individual motivational counseling sessions (20 to 40 minutes) within 6 weeks, conducted by an educated smoking cessation counselor. The smoking cessation counselor has been trained in motivational counseling techniques to this specific intervention.
Nicotine replacement therapy. Dose and form of nicotine replacement will be assessed individually using Fagerstr√∂m's Test for Nicotine Dependence.
Intervention patients will receive a smoking diary in which they can report smoking status and use of nicotine replacement therapy daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive usual treatment and care in the rheumatology outpatient clinic. This entails no or sporadic information about the impact of smoking on rheumatoid arthritis. Control patients will receive a smoking diary where they can report smoking status and use of nicotine replacement therapy daily. If a control patient expresses interest in smoking cessation counseling, we will refer to existing municipal smoking cessation interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive smoking cessation intervention</intervention_name>
    <description>The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.</description>
    <arm_group_label>Intensive smoking cessation intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients can be included in the study if they:

          -  Have been diagnosed with Rheumatoid Arthritis (RA). RA diagnosis is defined by the
             ACR criteria 1987/EULAR criteria 2010 - ICD-10: M05.9 (seropositive rheumatoid
             arthritis), M06.0 (seronegative rheumatoid arthritis), M06.9 rheumatoid arthritis
             (unspecified).

          -  &gt; 18 years of age

          -  Speak and understand Danish

          -  Self-reported daily smoker

          -  Stable low-moderate disease activity (DAS28 &lt; 5.1) for at least 3 months (assessed by
             rheumatologist)

          -  Stable in medical treatment for at least 3 months (assessed by rheumatologist).

        Exclusion Criteria:

        Patients will not be eligible to participate in the study if they:

          -  Have a scheduled treatment change, within the next month (assessed by rheumatologist)

          -  Are pregnant and/or breastfeeding

          -  Have received a steroid injection in the previous month before inclusion

          -  Are cognitively incapable of given informed consent or complete participation in the
             study.

        Excluded or eligible patients who do not want to participate will be registered in one of
        the following three categories 1) not meeting the inclusion criteria 2) refused to
        participate 3) other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ida Kristiane Roelsgaard, RN, PhD student</last_name>
    <phone>+ 45 3863 4 49</phone>
    <email>ida.kristiane.roelsgaard@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bente Appel Esbensen, PhD, RN</last_name>
    <phone>+45 38634056</phone>
    <email>bente.appel.esbensen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet - Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Roelsgaard, PhD student</last_name>
      <phone>+ 45 3863 44 49</phone>
      <email>ida.kristiane.roelsgaard@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 26, 2017</lastchanged_date>
  <firstreceived_date>September 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Bente Appel Esbensen</investigator_full_name>
    <investigator_title>Senior Researcher, Associate professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Smoking Cessation</keyword>
  <keyword>Disease Activity</keyword>
  <keyword>Clinical Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
